These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Rubboli A; Halperin JL Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515 [No Abstract] [Full Text] [Related]
9. Advances in antiplatelet therapy for acute coronary syndromes. Contractor H; Ruparelia N Postgrad Med J; 2012 Jul; 88(1041):391-6. PubMed ID: 22357775 [TBL] [Abstract][Full Text] [Related]
10. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody. Roldán V; Marín F Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516 [No Abstract] [Full Text] [Related]
11. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Tomasello SD; Tello-Montoliu A; Angiolillo DJ Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003 [TBL] [Abstract][Full Text] [Related]
12. The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Behan MW; Chew DP; Aylward PE Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. Deharo P; Pons C; Pankert M; Bonnet G; Quilici J; Grosdidier C; Beguin S; Morange P; Alessi MC; Bonnet JL; Cuisset T Int J Cardiol; 2013 Oct; 168(5):5004-5. PubMed ID: 23915522 [No Abstract] [Full Text] [Related]
14. Is it appropriate to compare the results from two clinical trials with one drug in common? Marrugat J; Vila J; Elosua R Rev Esp Cardiol (Engl Ed); 2013 Feb; 66(2):151-3. PubMed ID: 24775396 [No Abstract] [Full Text] [Related]
15. Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes. Aronow WS Postgrad Med; 2013 Jan; 125(1):51-8. PubMed ID: 23391671 [TBL] [Abstract][Full Text] [Related]
16. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Robinson A; Das K; Koshy SK; Das P Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050 [TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788 [TBL] [Abstract][Full Text] [Related]
18. Facts and controversies of aspirin and clopidogrel therapy. Faxon DP; Freedman JE Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409 [TBL] [Abstract][Full Text] [Related]
19. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient? Kern MJ Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555 [No Abstract] [Full Text] [Related]